Given the rapid accumulation of evidence, a meta-analysis is necessary to synthesize data from multiple trials, providing a quantitative estimate of the impact of SGLT2 inhibitors on cardiovascular death and HF-related hospitalizations. This evidence concerns the gene SLC5A2 and hydrops fetalis.